重组人粒细胞集落刺激因子联合抗生素治疗急性白血病化疗后中性粒细胞缺乏合并感染患者的临床效果
|
摘要
目的探究重组人粒细胞集落刺激因子联合抗生素治疗急性白血病(AL)化疗后中性粒细胞缺乏合并感染患者的临床效果。方法选取于我院接受治疗的AL化疗后中性粒细胞缺乏合并感染的80例患者作为观察对象,通过随机数表法将其分为对照组与研究组,各40例。对照组单纯予以抗生素治疗,研究组则在对照组的治疗基础上予以重组人粒细胞集落刺激因子治疗。比较两组的治疗效果。结果研究组的中性粒细胞恢复正常时间、体温恢复正常时间及抗生素使用时间均显著短于对照组(P<0.05)。治疗后,两组患者中性粒细胞、PCT、CRP、IL-6水平均优于治疗前,且研究组优于对照组(P<0.05)。治疗后,两组KPS评分均显著升高,且研究组高于对照组(P<0.05)。结论重组人粒细胞集落刺激因子联合抗生素治疗可以显著改善AL患者化疗后的中性粒细胞水平低下及感染情况,可促进患者恢复,加强患者自身的体质及功能状态,进而提高化疗的耐受性,因此该治疗方法具备临床推广价值。
Objective To explore the clinical effect of recombinant human granulocyte colony-stimulating factor combined with antibiotics in the treatment of acute leukemia(AL) patients with neutropenia complicated with infection after chemotherapy. Methods Eighty patients with neutropenia complicated with infection after chemotherapy for AL in our hospital were selected as the observation objects and divided into control group and study group by random number table method, with 40 cases in each group. The control group was treated with antibiotics only, while the study group was treated with recombinant human granulocyte colony-stimulating factor combined with antibiotics. The therapeutic effects of the two groups were compared. Results The neutrophil recovery time, body temperature recovery time and antibiotic use time in the study group were significantly shorter than those in the control group(P<0.05). After treatment, the levels of neutrophils,PCT, CRP and IL-6 in the two groups were better than those before treatment, and those in the study group were better than the control group(P<0.05). After treatment, the KPS scores of the two groups increased significantly, and that of the study group was higher than the control group(P<0.05). Conclusion Recombinant human granulocyte colony-stimulating factor combined with antibiotics can significantly improve the symptoms of low neutrophil level and infection in patients with AL after chemotherapy. It can promote the recovery of patients, strengthen their own physical and functional status,and then improve the tolerance of chemotherapy. Therefore, the treatment method has clinical popularization value.
Objective To explore the clinical effect of recombinant human granulocyte colony-stimulating factor combined with antibiotics in the treatment of acute leukemia(AL) patients with neutropenia complicated with infection after chemotherapy. Methods Eighty patients with neutropenia complicated with infection after chemotherapy for AL in our hospital were selected as the observation objects and divided into control group and study group by random number table method, with 40 cases in each group. The control group was treated with antibiotics only, while the study group was treated with recombinant human granulocyte colony-stimulating factor combined with antibiotics. The therapeutic effects of the two groups were compared. Results The neutrophil recovery time, body temperature recovery time and antibiotic use time in the study group were significantly shorter than those in the control group(P<0.05). After treatment, the levels of neutrophils,PCT, CRP and IL-6 in the two groups were better than those before treatment, and those in the study group were better than the control group(P<0.05). After treatment, the KPS scores of the two groups increased significantly, and that of the study group was higher than the control group(P<0.05). Conclusion Recombinant human granulocyte colony-stimulating factor combined with antibiotics can significantly improve the symptoms of low neutrophil level and infection in patients with AL after chemotherapy. It can promote the recovery of patients, strengthen their own physical and functional status,and then improve the tolerance of chemotherapy. Therefore, the treatment method has clinical popularization value.
引文
[1]刘允刚,邓玲慧,朱麒,等.恶性肿瘤化疗致中性粒细胞缺乏症治疗方案分析及疗效分析[J].中华卫生应急电子杂志,2017,3(6):348-352.
[2]郑洁,杨素,石杨茹,等.rhG-GSF联合抗菌药物对AL化疗后中性粒细胞缺乏合并感染患者血清炎症因子的影响[J].中华医院感染学杂志,2017,27(23):5344-5347.
[3]富洋,王宏胜,翟晓文,等.血液肿瘤儿童化疗后预防性使用重组人粒细胞/粒细胞-巨噬细胞集落刺激因子的疗效和安全性[J].肿瘤,2017,37(5):504-510.
[4]宫晨,熊慧华,熊华,等.比阿培南联合粒细胞集落刺激因子治疗化疗后高危中性粒细胞缺乏性发热56例临床观察[J].临床内科杂志,2016,33(7):485-487.
[5]左金曼,夏瑞祥.重组人粒细胞集落刺激因子联合抗生素治疗AL化疗后中性粒细胞缺乏合并感染患者的疗效[J].中国老年学杂志,2016,36(20):5064-5066.
[6]陈琼,刘隽,唐勇,等.重组人粒细胞-巨噬细胞集落刺激因子联合复方氯己定治疗急性髓系白血病化疗后口腔黏膜炎的临床观察[J].世界临床药物,2017,38(8):535-538.
[7]王环,李惠平,宋国红,等.预防性使用粒细胞集落刺激因子对乳腺癌辅助化疗所致中性粒细胞减少的影响[J].肿瘤,2016,36(11):1239-1245.
[8]郑海涛,李瑞芹,杨锭洪,等.rhG-CSF联合rhIL-11防治急性淋巴细胞白血病大剂量化疗后血细胞减少的研究[J].中国卫生检验杂志,2016,26(7):978-980,983.
[9]刘利珍,马康,马书田.不同剂量重组人粒细胞集落刺激因子注射液对恶性肿瘤化疗后白细胞下降的防治观察[J].中国医师杂志,2017,19(1):119-121.
[10]杨晟,何小慧,刘鹏,等.化疗后预防性使用重组人粒细胞集落刺激因子的持续时间及其影响因素[J].中华肿瘤杂志,2016,38(1):69.
[11]王月莉,张学虹,刘昊.重组人粒细胞集落刺激因子治疗白细胞减少症临床效果研究[J].中国煤炭工业医学杂志,2017,20(10):1158-1160.
[12]张平.十一味参芪片联合重组人粒细胞刺激因子治疗化疗后中性粒细胞减少症的疗效观察[J].现代药物与临床,2018,33(6):1472-1475.
[13]周燕萍,杨晓荣,白海燕,等.rhG-CSF治疗不同白细胞减少症的疗效与机制[J].现代医学,2016,44(12):1762-1765.
[14]冯敏,常思远,徐大千,等.重组人粒细胞巨噬细胞集落刺激因子对脓毒症模型小鼠的治疗作用[J].中国组织工程研究,2016,20(49):7391-7396.
[15]钟晓燕.AL化疗后粒细胞缺乏症应用牛脾注射液联合粒细胞集落刺激因子的疗效观察[J].临床医药文献电子杂志,2016,3(11):2190-2191.
[16]陈喜梅,蔡亚飞,吕转,等.重组人粒细胞集落刺激因子在乳腺癌化疗后应用的临床分析[J].中国实用医刊,2017,44(10):42.
[2]郑洁,杨素,石杨茹,等.rhG-GSF联合抗菌药物对AL化疗后中性粒细胞缺乏合并感染患者血清炎症因子的影响[J].中华医院感染学杂志,2017,27(23):5344-5347.
[3]富洋,王宏胜,翟晓文,等.血液肿瘤儿童化疗后预防性使用重组人粒细胞/粒细胞-巨噬细胞集落刺激因子的疗效和安全性[J].肿瘤,2017,37(5):504-510.
[4]宫晨,熊慧华,熊华,等.比阿培南联合粒细胞集落刺激因子治疗化疗后高危中性粒细胞缺乏性发热56例临床观察[J].临床内科杂志,2016,33(7):485-487.
[5]左金曼,夏瑞祥.重组人粒细胞集落刺激因子联合抗生素治疗AL化疗后中性粒细胞缺乏合并感染患者的疗效[J].中国老年学杂志,2016,36(20):5064-5066.
[6]陈琼,刘隽,唐勇,等.重组人粒细胞-巨噬细胞集落刺激因子联合复方氯己定治疗急性髓系白血病化疗后口腔黏膜炎的临床观察[J].世界临床药物,2017,38(8):535-538.
[7]王环,李惠平,宋国红,等.预防性使用粒细胞集落刺激因子对乳腺癌辅助化疗所致中性粒细胞减少的影响[J].肿瘤,2016,36(11):1239-1245.
[8]郑海涛,李瑞芹,杨锭洪,等.rhG-CSF联合rhIL-11防治急性淋巴细胞白血病大剂量化疗后血细胞减少的研究[J].中国卫生检验杂志,2016,26(7):978-980,983.
[9]刘利珍,马康,马书田.不同剂量重组人粒细胞集落刺激因子注射液对恶性肿瘤化疗后白细胞下降的防治观察[J].中国医师杂志,2017,19(1):119-121.
[10]杨晟,何小慧,刘鹏,等.化疗后预防性使用重组人粒细胞集落刺激因子的持续时间及其影响因素[J].中华肿瘤杂志,2016,38(1):69.
[11]王月莉,张学虹,刘昊.重组人粒细胞集落刺激因子治疗白细胞减少症临床效果研究[J].中国煤炭工业医学杂志,2017,20(10):1158-1160.
[12]张平.十一味参芪片联合重组人粒细胞刺激因子治疗化疗后中性粒细胞减少症的疗效观察[J].现代药物与临床,2018,33(6):1472-1475.
[13]周燕萍,杨晓荣,白海燕,等.rhG-CSF治疗不同白细胞减少症的疗效与机制[J].现代医学,2016,44(12):1762-1765.
[14]冯敏,常思远,徐大千,等.重组人粒细胞巨噬细胞集落刺激因子对脓毒症模型小鼠的治疗作用[J].中国组织工程研究,2016,20(49):7391-7396.
[15]钟晓燕.AL化疗后粒细胞缺乏症应用牛脾注射液联合粒细胞集落刺激因子的疗效观察[J].临床医药文献电子杂志,2016,3(11):2190-2191.
[16]陈喜梅,蔡亚飞,吕转,等.重组人粒细胞集落刺激因子在乳腺癌化疗后应用的临床分析[J].中国实用医刊,2017,44(10):42.